Draco

Draco Therapeutics is a biotechnology company focused on the development of broad-spectrum antiviral therapies based on the DRACO (Double-stranded RNA Activated Caspase Oligomerizer) technology. Originally developed at MIT Lincoln Laboratory, the DRACO platform utilizes chimeric proteins designed to selectively induce apoptosis in virus-infected cells by detecting long double-stranded RNA (dsRNA) produced during viral replication. The company aims to create a universal treatment effective against a wide range of viral pathogens, including influenza, rhinovirus, and hemorrhagic fevers. Currently in the pre-clinical stage, Draco Therapeutics seeks to translate this innovative mechanism into clinical applications to address unmet needs in infectious disease management.